Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MT-CO3 pseudogene 29 (MTCO3P29) is a non-coding locus derived from the mitochondrial gene MT-CO3 (mitochondrially encoded cytochrome c oxidase III), but contains sequence alterations or interruptions that render it nonfunctional as a protein-coding gene. MT-CO3 pseudogenes, including MTCO3P29, are remnants of gene duplication or retrotransposition events and do not encode active protein or participate in mitochondrial respiratory chain complex IV function. The prefix "pseudogene" and its designation (29) indicate that it is one of many such nonfunctional copies or fragments in the genome, and not a functional biological target. No evidence suggests it is a therapeutic target or involved in biological pathways, drug response, or disease, outside of hypothetical, rare pseudogene regulatory effects which are not established for MTCO3P29. In contrast, the canonical gene (MT-CO3) encodes cytochrome c oxidase subunit III, a crucial component of mitochondrial complex IV, which has well-established roles in oxidative phosphorylation, electron transport, and diseases such as mitochondrial myopathies and Leber hereditary optic neuropathy (LHON)[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MT-CO3 pseudogene 29 (MTCO3P29).